RE:RE:RE:Placebo effect??The PR of Jan 13 has already said that T2 results to be released by mid Feb and analsysis of root cause of T1 placebo anomaly by end of Feb. You will have to sit tight until then and expect SP to drift lower until those releases as shareholders become nervous and sell.
The real risk here is not lack of communication from management since they have already laid out their timeline, but possiblility that T2 results mirror what we saw in T1. This is possible if the cause of the placebo effect was not an error but embedded in the trial design (diet, concomitant drugs, etc.). If that occurs expect SP to get to $0.50 range which I think would be a tremendous buying opportunity since we know Capre works and they would have to do another P3 trial to prove this. On the other hand if T2 results are positive and some type of error is discovered in those 5 sites of T1 then SP could easily be back in the $2 range.